Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves all resolutions


EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology AG: Extraordinary Shareholders' Meeting approves all
resolutions

06.01.2016 / 12:05
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd. approves all
resolutions

Schlieren (Zurich), Switzerland, January 6, 2016 - Cytos Biotechnology Ltd
("Cytos" or the "Company"), announced today that its shareholders have approved
all resolutions at today's Extraordinary Shareholders' Meeting with overwhelming
majority. These resolutions, among other things, consist of an ordinary capital
increase of around 392 million shares which will be used to acquire Kuros
Biosurgery Ltd. After the capital increase, a total of around 500 million Cytos
shares with a nominal value of CHF 0.01 each will be issued and outstanding.

The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took place at
the Company's headquarters in Schlieren (Zurich), Switzerland. It was attended
by 92 shareholders. 23'555'497 shares or 21.8% of a total of 108'015'276 shares
were represented.

Additional information can be retrieved in our press releases dated December 3,
2015 and
December 15, 2015.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the SIX
Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

 

End of ad hoc announcement

+++++
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=FJIHCYEQEX
Document title: Cytos_EGM_160106

--------------------------------------------------------------------------------
06.01.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  Cytos Biotechnology AG

          Wagistr. 25

          8952  Schlieren

          Switzerland

Phone:    +41 44 733 4747

Fax:      +41 44 733 4740

E-mail:info@cytos.com

Internet: www.cytos.com

ISIN:     CH0011025217, CH0029060735

Valor:    -

Listed:   Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market
in Frankfurt ; SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
427335  06.01.2016 
 

 


Das könnte Sie auch interessieren: